Search results for Ibalizumab

Ibalizumab Biosimilar – Anti-CD4 D3 domain mAb – Research Grade, ProteoGenix, PX-TA1174

Description of Ibalizumab Biosimilar - Anti-CD4 D3 domain mAb - Research Grade Introduction Ibalizumab Biosimilar, also known as Anti-CD4 D3 domain mAb, is a monoclonal antibody that targets the CD4 receptor on immune cells. This biosimilar is currently being developed as a potential therapeutic option for various diseases, particularly HIV/AIDS. In this article, we will explore the structure, activity, and potential applications of Ibalizumab Biosimilar in the field of medicine. Structure of Ibalizumab Biosimilar Ibalizumab Biosimilar is a recombinant humanized IgG4 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Ibalizumab Biosimilar is responsible for binding to the CD4 receptor, while the constant region determines the antibody’s effector functions. Activity of Ibalizumab Biosimilar The primary function of Ibalizumab Biosimilar is to inhibit the interaction between the CD4 receptor and the HIV envelope protein, gp120. This interaction is essential for HIV to enter and infect immune cells. By blocking this interaction, Ibalizumab Biosimilar prevents HIV from replicating and spreading, thereby reducing the viral load in the body. Additionally, Ibalizumab Biosimilar has been shown to have a unique mechanism of action compared to other anti-HIV drugs. It binds to a different site on the CD4 receptor, known as the D3 domain, which is not targeted by other HIV therapies. This makes Ibalizumab Biosimilar a potential option for patients who have developed resistance to other anti-HIV drugs. Applications of Ibalizumab Biosimilar Ibalizumab Biosimilar is currently being studied as a potential treatment for HIV/AIDS. It has shown promising results in clinical trials, with some patients achieving undetectable viral loads after treatment with Ibalizumab Biosimilar. This makes it a potential option for patients who have failed to respond to other anti-HIV therapies. Apart from HIV, Ibalizumab Biosimilar has also shown potential in the treatment of other diseases. It has been studied in animal models for its potential use in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Additionally, Ibalizumab Biosimilar has also been investigated for its potential to prevent organ rejection in transplant patients. Research Grade Ibalizumab Biosimilar Ibalizumab Biosimilar is currently in the research grade stage, which means it is being studied and evaluated for its safety and efficacy in treating diseases. This is a crucial step in the development of any new drug, as it helps to determine the appropriate dosage, potential side effects, and overall effectiveness of the medication. Conclusion In conclusion, Ibalizumab Biosimilar is a promising monoclonal antibody that targets the CD4 receptor and has shown potential in the treatment of HIV/AIDS and other diseases. Its unique mechanism of action and potential for use in patients who have developed resistance to other drugs make it a valuable addition to the current arsenal of anti-HIV therapies. As research on Ibalizumab Biosimilar continues, it may prove to be a valuable therapeutic option for various diseases, providing hope for patients and healthcare providers alike.

Ibalizumab, Abbexa, abx831129

Ibalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD4 D3 domain, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8, 5.

Ibalizumab ELISA Kit, ProteoGenix, KPTX136

Description of Ibalizumab ELISA Kit The Structure of Ibalizumab ELISA Kit Ibalizumab ELISA Kit is a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) kit designed for the detection and quantification of Ibalizumab, a monoclonal antibody used as a therapeutic agent in the treatment of HIV-1 infection. The kit is composed of several components including a microplate coated with Ibalizumab-specific antibodies, a detection antibody, and a colorimetric substrate for signal detection. The microplate used in the Ibalizumab ELISA Kit is made of polystyrene and has 96 wells, each of which is coated with a specific amount of Ibalizumab-specific antibodies. These antibodies are produced through recombinant DNA technology and are highly specific for Ibalizumab, ensuring accurate and reliable results. The microplate is designed to capture and bind Ibalizumab present in the sample, allowing for the quantification of the antibody. The detection antibody used in the kit is a biotinylated monoclonal antibody that specifically binds to Ibalizumab. This antibody is labeled with biotin, a vitamin B derivative, which allows for its detection through the use of a streptavidin-horseradish peroxidase (HRP) conjugate. The HRP enzyme catalyzes a colorimetric reaction with the substrate, producing a visible signal that can be measured and quantified. The Activity of Ibalizumab ELISA Kit The Ibalizumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Ibalizumab in various biological samples, including serum, plasma, and cell culture supernatants. The kit has a wide dynamic range of detection, allowing for the accurate measurement of Ibalizumab levels in both high and low concentrations. The activity of the Ibalizumab ELISA Kit is based on the principle of competitive ELISA, where the amount of Ibalizumab present in the sample competes with a fixed amount of Ibalizumab conjugated to the microplate for binding to the detection antibody. The signal produced is inversely proportional to the amount of Ibalizumab present in the sample, allowing for the quantification of the antibody. The sensitivity of the kit is enhanced by the use of a highly specific detection antibody and a colorimetric substrate that produces a strong signal. This allows for the detection of Ibalizumab in samples with low concentrations, making the kit suitable for both research and clinical applications. The Application of Ibalizumab ELISA Kit The Ibalizumab ELISA Kit has several applications, including the measurement of Ibalizumab levels in patient samples for monitoring treatment response and the evaluation of pharmacokinetics and pharmacodynamics of Ibalizumab in clinical trials. The kit can also be used in research studies to assess the presence and levels of Ibalizumab in different biological samples. One of the major applications of the Ibalizumab ELISA Kit is in the development and evaluation of Ibalizumab as a therapeutic agent for the treatment of HIV-1 infection. Ibalizumab is a monoclonal antibody that targets the CD4 binding site of the HIV-1 virus, preventing it from entering and infecting host cells. The ELISA kit allows for the measurement of Ibalizumab levels in patient samples, providing valuable information on its efficacy and pharmacokinetics. In addition, the Ibalizumab ELISA Kit can also be used to assess the potential for drug-drug interactions between Ibalizumab and other medications in co-treated patients. This is important for the safe and effective use of Ibalizumab in combination therapy with other antiretroviral drugs. In conclusion, the Ibalizumab ELISA Kit is a valuable tool for the detection and quantification of Ibalizumab, providing important information for both research and clinical applications

Ibalizumab ELISA Kit, Abbexa, abx395025

Ibalizumab ELISA Kit is a quantitative ELISA kit for detection of Ibalizumab.Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen. Ibalizumab demonstrates a novel mechanism of action as a CD4-directed postattachment inhibitor and has a favorable pharmacokinetic profile that allows for a dosing interval of every 14 days after an initial loading dose. Clinical studies have demonstrated reasonably substantial antiretroviral activity with ibalizumab among a complex patient population with advanced HIV-1 infection who are receiving an optimized background regimen, where limited therapeutic options exist. Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. Resistance to ibalizumab has also been observed via reduced expression or loss of the potential N-linked glycosylation sites in the V5 loop of the envelope glycoprotein 120. The mechanism of action, pharmacokinetic parameters, efficacy, and safety of ibalizumab present an advance in the management of MDR HIV-1 infection. Future studies and postmarketing experience will further determine longer-term clinical efficacy, safety, and resistance data for ibalizumab.

Ibalizumab Biosimilar - Research Grade, ichor.bio, ICH5029

Detects human CD4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ibalizumab.

Research Grade Ibalizumab (HF998016), abinScience, HF998016